Patients with prostate cancer treated by ADT have significantly higher fibrinogenemia than healthy control

World Journal of Urology

Volumn 31, Issue 2, 2013, Pages 289-292

  Ziaran, Stanislav ^a   Goncalves, Frederico Manuel ^a   Breza Sr , Jan ^a  

^a UNIVERSITY HOSPITAL BRATISLAVA   (Slovakia)

Author keywords

Androgen deprivation therapy; Fibrinogen; Lipoproteins; Prostate cancer

Indexed keywords

EID: 84876449771     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-012-0926-x     Document Type: Article

References (29)

1. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics 2010. CA Cancer J Clin 60: 277-300.
2. Surveillance Epidemiology and End Results. SEER Stat Fact Sheets: Prostate Cancer. 2008 Available at: http://seer. cancer. gov/statfacts/html/prost. html Accessed 25 July 2011.
3. Tangen CM, Faulkner JR, Crawford ED et al (2003) Ten-year survival in patients with metastatic prostate cancer. Clin Prostate Cancer 2: 41-45.
4. Huggins C, Stevens RE Jr, Hodges CV (1941) Studies on prostatic cancer. II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 43: 209-223.
5. Chodak GW, Keane T, Klotz L (2002) Critical evaluation of hormonal therapy for carcinoma of the prostate. Urology 60: 201-208.
6. Bolla M, Collette L, Blank L et al (2002) Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360: 103-106.
7. Chodak GW (1998) Comparing treatments for localized prostate cancer: persisting uncertainty. JAMA 280: 1008-1010.
8. Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS (2005) Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer 103: 1615-1624.
9. Green HJ, Pakenham KI, Headley BC et al (2004) Quality of life compared during pharmacological treatments and clinical monitoring for non-localized prostate cancer: a randomized controlled trial. BJU Int 93: 975-979.
10. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS (2006) Risk of the "androgen deprivation syndrome" in men receiving androgen deprivation for prostate cancer. Arch Intern Med 166: 465-471.
11. Alibhai SM, Gogov S, Allibhai Z (2006) Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: a systematic literature review. Crit Rev Oncol Hematol 60: 201-215.
12. Ziaran S, Goncalves FM, Breza J (2011) Bone mineral density, pathological fractures and bisphosphonate therapy in prostate cancer patients on androgen deprivation therapy. Endocr Regul 45: 199-204.
13. Daniell HW, Dunn SR, Fergusson DW, Lomas G, Niazi Z, Srtatte PT (2000) Progressive osteoporosis during andorgen deprivation therapy for prostate cancer. J Urol 163: 181-186.
14. Oefelein MG, Ricchiuti V, Conrad W, Resnick MI (2002) Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 168(3): 1005-1007.
15. Smith MR, Lee H, Nathan DM (2006) Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 91: 1305-1308.
16. Basaria S, Muller DC, Carducci MA, Egan J, Dobs AS (2006) Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer 106(3): 581-588.
17. Smith JC, Bennett S, Evans LM, Kynaston HG, Parmar M, Mason MD, Cockcroft JR, Scanlon MF, Davies JS (2001) The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 86: 4261-4267.
18. Haseen F, Murray LJ, Cardwell CR, O'Sullivan JM, Cantwell MM (2010) The effect of androgen deprivation therapy on body composition in men with prostate cancer: systematic review and meta-analysis. J Cancer Surviv 4(2): 128-139.
19. Danesh J, Lewington S, Thompson SG, Lowe GD, Collins R, Kostis JB, Wilson AC, Folsom AR, Wu K, Benderly M et al (2005) Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 294(14): 1799-1809.
20. Kaptoge S, White IR, Thompson SG, Wood AM, Lewington S, Lowe GD, Danesh J (2007) Associations of plasma fibrinogen levels with established cardiovascular disease risk factors, inflammatory markers, and other characteristics: individual participant meta-analysis of 154, 211 adults in 31 prospective studies: the fibrinogen studies collaboration. Am J Epidemiol 166(8): 867-879.
21. Palmieri V, Celentano A, Roman MJ, de Simone G, Best L, Lewis MR, Robbins DC, Fabsitz RR, Howard BV, Devereux RB (2003) Relation of fibrinogen to cardiovascular events is independent of preclinical cardiovascular disease: the strong heart study. Am Heart J 145(3): 467-474.
22. Yan RT, Fernandes V, Yan AT, Cushman M, Redheuil A, Tracy R, Vogel-Claussen J, Bahrami H, Nasir K, Bluemke DA et al (2010) Fibrinogen and left ventricular myocardial systolic function: the multi-ethnic study of atherosclerosis (MESA). Am Heart J 160(3): 479-486.
23. Fibrinogen Studies Collaboration (2005) Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 294: 1799-1809.
24. The Emerging Risk Factors Collaboration (2010) C-reactive protein concentration and the risk of coronary heart disease, stroke, and mortality. Lancet 375: 132-140.
25. Lowe GDO (1995) Fibrinogen and cardiovascular disease: historical introduction. Eur Heart J 16(Suppl A): 2-5.
26. Khosla S, Atkinson EJ, Dunstan CR, O'Fallon WM (2002) Effect of estrogen versus testosterone on circulating osteoprotegerin and other cytokine levels in normal elderly men. J Clin Endocrinol Metab 87: 1550-1554.
27. Maggio M, Blackford A, Taub D, Carducci M, Ble A, Metter EJ, Braga-Basaria M, Dobs A, Basaria S (2006) Circulating inflammatory cytokine expression in men with prostate cancer undergoing androgen deprivation therapy. J Androl 27: 725-728.
28. Elsberger B, Lankston L, McMillan DC, Underwood MA, Edwards J (2011) Presence of tumoural C-reactive protein correlates with progressive prostate cancer. Prostate Cancer Prostatic Dis 14(2): 122-128.
29. Danesh J, Collins R, Peto R, Lowe GDO (2000) Haematocrit, viscosity, erythrocyte sedimentation rate: meta-analyses of prospective studies of coronary heart disease. Eur Heart J 21: 515-520.